Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Hodgkin’s Lymphoma | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

Login to access report north_east
Contact sales account_box

The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the label expansion of Adcetris and the approval of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).

CONTENT OVERVIEW

From disease basics to insightful analysis of market dynamics, Hodgkin’s lymphoma | Disease Landscape & Forecast | US and EU5 provides comprehensive disease coverage addressing critical aspects of the Hodgkin’s lymphoma pharmaceutical market based on primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug-treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a topline review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.

WHAT YOU WILL LEARN IN THIS CONTENT

  • How large is the drug-treatable Hodgkin’s lymphoma population and how will drug-treatment rates change over time?
  • What is the current state of treatment in Hodgkin’s lymphoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in Hodgkin’s lymphoma? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the Hodgkin’s lymphoma market, and how will the market evolve over the forecast period?

KEY DRUGS COVERED

Adcetris, Opdivo, Keytruda, Farydak, Rituxan/MabThera

KEY COMPANIES MENTIONED

  • Seattle Genetics
  • Takeda
  • Bristol-Myers Squibb
  • Merck & Co.
  • Novartis
  • Roche/Genentech
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east